Business Description
Ascelia Pharma AB
ISIN : SE0010573113
Compare
Compare
Traded in other countries / regions
ACE.Sweden7ZA.GermanyACEs.UK IPO Date
2020-12-10Description
Ascelia Pharma AB is an oncology-dedicated drug development company located in Malmo Sweden focused on orphan oncology It develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway The company has two drug candidates Orviglance and Oncoral in clinical development.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.87 | |||||
| Equity-to-Asset | 0.5 | |||||
| Debt-to-Equity | 0.71 | |||||
| Debt-to-EBITDA | -0.57 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 5 | |||||
| 3-Year EPS without NRI Growth Rate | 5.1 | |||||
| 3-Year FCF Growth Rate | -4.7 | |||||
| 3-Year Book Growth Rate | -35.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 46.27 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 55.21 | |||||
| 9-Day RSI | 52.73 | |||||
| 14-Day RSI | 51.21 | |||||
| 6-1 Month Momentum % | -71.69 | |||||
| 12-1 Month Momentum % | 18.7 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.7 | |||||
| Quick Ratio | 2.7 | |||||
| Cash Ratio | 2.16 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -6.2 | |||||
| Shareholder Yield % | -4.87 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -82.35 | |||||
| ROA % | -59.43 | |||||
| ROIC % | -83.04 | |||||
| 3-Year ROIIC % | 433.88 | |||||
| ROC (Joel Greenblatt) % | -5553.28 | |||||
| ROCE % | -70.41 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 2.77 | |||||
| EV-to-EBIT | -4.14 | |||||
| EV-to-Forward-EBIT | -3.27 | |||||
| EV-to-EBITDA | -4.14 | |||||
| EV-to-Forward-EBITDA | -3.27 | |||||
| EV-to-FCF | -3.57 | |||||
| Earnings Yield (Greenblatt) % | -24.17 | |||||
| FCF Yield % | -30.23 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Ascelia Pharma AB Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.11 | ||
| Beta | 0.71 | ||
| Volatility % | 237.08 | ||
| 14-Day RSI | 51.21 | ||
| 14-Day ATR (€) | 0.02519 | ||
| 20-Day SMA (€) | 0.14523 | ||
| 12-1 Month Momentum % | 18.7 | ||
| 52-Week Range (€) | 0.111 - 0.852379 | ||
| Shares Outstanding (Mil) | 96.08 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Ascelia Pharma AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ascelia Pharma AB Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Ascelia Pharma AB Frequently Asked Questions
What is Ascelia Pharma AB(FRA:7ZA)'s stock price today?
The current price of FRA:7ZA is €0.16. The 52 week high of FRA:7ZA is €0.85 and 52 week low is €0.11.
When is next earnings date of Ascelia Pharma AB(FRA:7ZA)?
The next earnings date of Ascelia Pharma AB(FRA:7ZA) is 2025-02-07.
Does Ascelia Pharma AB(FRA:7ZA) pay dividends? If so, how much?
Ascelia Pharma AB(FRA:7ZA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers